CN112618414A - 一种祛眼袋的眼贴及其制备方法和应用 - Google Patents
一种祛眼袋的眼贴及其制备方法和应用 Download PDFInfo
- Publication number
- CN112618414A CN112618414A CN202110013939.1A CN202110013939A CN112618414A CN 112618414 A CN112618414 A CN 112618414A CN 202110013939 A CN202110013939 A CN 202110013939A CN 112618414 A CN112618414 A CN 112618414A
- Authority
- CN
- China
- Prior art keywords
- parts
- eye patch
- skin
- eye
- hydroxyacetophenone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 84
- TXFPEBPIARQUIG-UHFFFAOYSA-N 4'-hydroxyacetophenone Chemical compound CC(=O)C1=CC=C(O)C=C1 TXFPEBPIARQUIG-UHFFFAOYSA-N 0.000 claims abstract description 52
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 39
- 230000037303 wrinkles Effects 0.000 claims abstract description 30
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 27
- 239000003998 snake venom Substances 0.000 claims abstract description 27
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 claims abstract description 27
- 229960000401 tranexamic acid Drugs 0.000 claims abstract description 27
- 101000761020 Dinoponera quadriceps Poneritoxin Proteins 0.000 claims abstract description 26
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims abstract description 24
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims abstract description 23
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 claims abstract description 23
- 229920001184 polypeptide Polymers 0.000 claims abstract description 23
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 23
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 claims abstract description 23
- 229940015975 1,2-hexanediol Drugs 0.000 claims abstract description 22
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 claims abstract description 22
- FHKSXSQHXQEMOK-UHFFFAOYSA-N hexane-1,2-diol Chemical compound CCCCC(O)CO FHKSXSQHXQEMOK-UHFFFAOYSA-N 0.000 claims abstract description 22
- 239000011975 tartaric acid Substances 0.000 claims abstract description 22
- 235000002906 tartaric acid Nutrition 0.000 claims abstract description 22
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims abstract description 19
- WSGCRSMLXFHGRM-DEVHWETNSA-N (2s)-2-[[(2s)-6-amino-2-[[(2s,3r)-2-[[(2s,3r)-2-[[(2s)-6-amino-2-(hexadecanoylamino)hexanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxybutanoyl]amino]hexanoyl]amino]-3-hydroxypropanoic acid Chemical compound CCCCCCCCCCCCCCCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O WSGCRSMLXFHGRM-DEVHWETNSA-N 0.000 claims abstract description 14
- 229960001367 tartaric acid Drugs 0.000 claims abstract description 10
- QUVCFQAHXXKABX-UHFFFAOYSA-K C(CO)(=O)[O-].O[Al+]O Chemical compound C(CO)(=O)[O-].O[Al+]O QUVCFQAHXXKABX-UHFFFAOYSA-K 0.000 claims abstract description 8
- 239000002537 cosmetic Substances 0.000 claims abstract description 8
- 238000002156 mixing Methods 0.000 claims description 16
- 239000000084 colloidal system Substances 0.000 claims description 15
- 239000011248 coating agent Substances 0.000 claims description 12
- 238000000576 coating method Methods 0.000 claims description 12
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 11
- BWZOPYPOZJBVLQ-UHFFFAOYSA-K aluminium glycinate Chemical compound O[Al+]O.NCC([O-])=O BWZOPYPOZJBVLQ-UHFFFAOYSA-K 0.000 claims description 10
- 239000012530 fluid Substances 0.000 claims description 7
- 235000011837 pasties Nutrition 0.000 claims description 7
- 238000005303 weighing Methods 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 6
- UTUUIUQHGDRVPU-UHFFFAOYSA-K aluminum;2-aminoacetate;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Al+3].NCC([O-])=O UTUUIUQHGDRVPU-UHFFFAOYSA-K 0.000 claims description 4
- 208000003351 Melanosis Diseases 0.000 claims description 3
- 206010014970 Ephelides Diseases 0.000 claims description 2
- 210000003491 skin Anatomy 0.000 abstract description 57
- 230000000694 effects Effects 0.000 abstract description 16
- 210000004027 cell Anatomy 0.000 abstract description 7
- 230000003647 oxidation Effects 0.000 abstract description 6
- 238000007254 oxidation reaction Methods 0.000 abstract description 6
- 210000001519 tissue Anatomy 0.000 abstract description 5
- 230000019612 pigmentation Effects 0.000 abstract description 4
- 230000001815 facial effect Effects 0.000 abstract description 3
- 206010003694 Atrophy Diseases 0.000 abstract description 2
- 230000037444 atrophy Effects 0.000 abstract description 2
- 230000002500 effect on skin Effects 0.000 abstract description 2
- 230000006872 improvement Effects 0.000 abstract description 2
- 210000002510 keratinocyte Anatomy 0.000 abstract description 2
- 230000002000 scavenging effect Effects 0.000 abstract description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 26
- 208000026935 allergic disease Diseases 0.000 description 26
- 230000007815 allergy Effects 0.000 description 26
- 238000003756 stirring Methods 0.000 description 25
- 235000011187 glycerol Nutrition 0.000 description 24
- 239000000843 powder Substances 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 230000002829 reductive effect Effects 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 7
- 238000011156 evaluation Methods 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 239000002245 particle Substances 0.000 description 7
- 239000008213 purified water Substances 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 235000002673 Dioscorea communis Nutrition 0.000 description 5
- 241000544230 Dioscorea communis Species 0.000 description 5
- 208000002197 Ehlers-Danlos syndrome Diseases 0.000 description 5
- 208000035753 Periorbital contusion Diseases 0.000 description 5
- 230000032683 aging Effects 0.000 description 5
- 238000005520 cutting process Methods 0.000 description 5
- 230000014759 maintenance of location Effects 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 238000004806 packaging method and process Methods 0.000 description 5
- 230000009759 skin aging Effects 0.000 description 5
- 235000019640 taste Nutrition 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 102000008186 Collagen Human genes 0.000 description 4
- 108010035532 Collagen Proteins 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 4
- 229920001436 collagen Polymers 0.000 description 4
- 210000004207 dermis Anatomy 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- 230000009965 odorless effect Effects 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 206010033675 panniculitis Diseases 0.000 description 4
- 210000004304 subcutaneous tissue Anatomy 0.000 description 4
- 230000002087 whitening effect Effects 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 208000012641 Pigmentation disease Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- -1 amide compound Chemical class 0.000 description 3
- 230000003712 anti-aging effect Effects 0.000 description 3
- 210000004177 elastic tissue Anatomy 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000037394 skin elasticity Effects 0.000 description 3
- 230000000391 smoking effect Effects 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- PLRXBMPPQBKJQV-UHFFFAOYSA-N 1,3-bis(4-hydroxyphenyl)propan-2-one Chemical compound C1=CC(O)=CC=C1CC(=O)CC1=CC=C(O)C=C1 PLRXBMPPQBKJQV-UHFFFAOYSA-N 0.000 description 2
- MVNVIVWSAFEIII-UHFFFAOYSA-N 1-(4-hydroxyphenyl)ethanone Chemical compound CC(=O)C1=CC=C(O)C=C1.CC(=O)C1=CC=C(O)C=C1 MVNVIVWSAFEIII-UHFFFAOYSA-N 0.000 description 2
- 229940073735 4-hydroxy acetophenone Drugs 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 230000001153 anti-wrinkle effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 235000019658 bitter taste Nutrition 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 235000003715 nutritional status Nutrition 0.000 description 2
- 210000004279 orbit Anatomy 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 241000208327 Apocynaceae Species 0.000 description 1
- 235000008658 Artemisia capillaris Nutrition 0.000 description 1
- 241000092668 Artemisia capillaris Species 0.000 description 1
- 235000003069 Artemisia scoparia Nutrition 0.000 description 1
- 241001249148 Artemisia scoparia Species 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000442274 Heteropappus Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 208000037093 Menstruation Disturbances Diseases 0.000 description 1
- 206010027339 Menstruation irregular Diseases 0.000 description 1
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 1
- 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 description 1
- 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 244000184734 Pyrus japonica Species 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 208000036944 Skin dystrophies Diseases 0.000 description 1
- 206010040844 Skin exfoliation Diseases 0.000 description 1
- 208000028990 Skin injury Diseases 0.000 description 1
- 208000010340 Sleep Deprivation Diseases 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 240000004584 Tamarindus indica Species 0.000 description 1
- 235000004298 Tamarindus indica Nutrition 0.000 description 1
- GYDJEQRTZSCIOI-UHFFFAOYSA-N Tranexamic acid Chemical compound NCC1CCC(C(O)=O)CC1 GYDJEQRTZSCIOI-UHFFFAOYSA-N 0.000 description 1
- 241000219094 Vitaceae Species 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 101800002700 Waglerin-1 Proteins 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 208000002029 allergic contact dermatitis Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000005282 brightening Methods 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000000701 coagulant Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- JMFRWRFFLBVWSI-NSCUHMNNSA-N coniferol Chemical compound COC1=CC(\C=C\CO)=CC=C1O JMFRWRFFLBVWSI-NSCUHMNNSA-N 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000035618 desquamation Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 229940015826 dihydroxyaluminum aminoacetate Drugs 0.000 description 1
- 150000002009 diols Chemical class 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 238000010410 dusting Methods 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 210000000887 face Anatomy 0.000 description 1
- 210000001097 facial muscle Anatomy 0.000 description 1
- 238000005562 fading Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 210000001061 forehead Anatomy 0.000 description 1
- 238000010528 free radical solution polymerization reaction Methods 0.000 description 1
- 229920001002 functional polymer Polymers 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 235000021021 grapes Nutrition 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 239000012263 liquid product Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000002232 neuromuscular Effects 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 208000001297 phlebitis Diseases 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000001242 postsynaptic effect Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 230000005808 skin problem Effects 0.000 description 1
- 230000036558 skin tension Effects 0.000 description 1
- 230000036555 skin type Effects 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 210000004003 subcutaneous fat Anatomy 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 210000000106 sweat gland Anatomy 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009967 tasteless effect Effects 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000002435 venom Substances 0.000 description 1
- 210000001048 venom Anatomy 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 230000002747 voluntary effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/0208—Tissues; Wipes; Patches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/35—Ketones, e.g. benzophenone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/58—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing atoms other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur or phosphorus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/673—Vitamin B group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/81—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
- A61K8/8141—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides or nitriles thereof; Compositions of derivatives of such polymers
- A61K8/8147—Homopolymers or copolymers of acids; Metal or ammonium salts thereof, e.g. crotonic acid, (meth)acrylic acid; Compositions of derivatives of such polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/005—Preparations for sensitive skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
- A61K2800/5922—At least two compounds being classified in the same subclass of A61K8/18
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Cosmetics (AREA)
Abstract
本发明适用于化妆品技术领域,提供了一种祛眼袋的眼贴及其制备方法和应用,该眼贴包括以下组分:甘油、聚丙烯酸钠、甘羟铝、EDTA‑2Na、酒石酸、传明酸、烟酰胺、蛇毒肽、棕榈酰五肽‑4、透皮多肽、1,2‑己二醇、对羟基苯乙酮、水。本发明提供的眼贴对面部肤色暗沉、色素沉着等肌肤问题具有明显的改善作用;还具有清除自由基、抗氧化、提高角质细胞的细胞活力,修复皮肤组织的作用;可改善面部皮肤组织松弛萎缩导致的皱纹,对眼袋具有一定程度的驱除作用。
Description
技术领域
本发明属于化妆品技术领域,尤其涉及一种祛眼袋的眼贴及其制备方法和应用。
背景技术
目前,产生皱纹的原因一般如下:
(1)体内及皮肤水分不足:我们知道皮肤的最外层为角质层,角质层可以从体内供给水分,也可以从体外吸收水分,使皮肤保持适度的水分含量。一般来说,皮肤含水量在10~20%最合适,若低于10%,皮肤呈干燥状态,即显得粗糙松弛,时间长了,就会出现皱纹。
(2)精神因素:经常闷闷不乐,急躁,孤僻,常常在面部表现出愁苦、紧张、拘谨的表情,这种表情牵动表情肌而产生纵向或横向的皱纹,使人逐渐出现衰老现象。
(3)长期睡眠不足:经常睡眠不足,会使皮肤的调节功能受损,致使容颜憔悴,容易衰老起皱。
(4)过度曝晒:过度曝晒可以造成皮肤损伤,使面部、颈部、手部的皮肤变干、变薄、失去弹性,使弹力纤维和胶质纤维失去正常的功能,皮肤逐渐变松起皱。
(5)营养状况:如果身体营养状况好,皮肤的营养供应充足,皮下组织丰满,皱纹就出现的晚;如营养状况不佳,致使皮肤肌肉组织营养不良,引起皮肤粗糙和松弛,容易产主皱纹。
(6)洗脸水温度过高:洗脸水以30 摄氏度左右的温水最合适,如果水温太高,皮肤的皮脂和水分会被热气所吸收,而使皮肤干燥,日久天长逐渐在脸部产生皱纹。
(7)化妆品使用不当:使用不适当的化妆品会破坏皮肤的质地,过多的扑粉也会使面部出现细密的小皱纹。
(8)过度吸烟、饮酒:长期过度吸烟、饮酒会加速皮肤的老化、从而过早产生皱纹,使人显得苍老憔悴。
皮肤衰老的原因如下:
(1)内在因素:皮肤附属器官功能的自然减退例如皮肤的汗腺、皮肤腺功能降低,分泌物减少,使皮肤的皮肤膜、角质层缺乏滋润而干燥,造成干纹、脱皮现象。由于皮肤新陈代谢减慢,真皮内的保湿因子减少,使得真皮内弹力纤维和胶原纤维功能减退,造成皮肤张力,弹力减弱,使皮肤容易出现皱纹。面部的皮肤较身体其他部位额皮肤薄。由于皮肤的营养障碍,使得皮下脂肪储存逐渐减少,细胞和纤维组织营养不良,性能下降。生物体内活性酶逐渐减少,身体各方面机能减退,使得大量的自由基破坏人体细胞,使细胞死亡。超氧自由基更会引发体内脂质过氧化,加快皮肤的衰老过程,并可诱发皮肤病变等,严重危害人体健康。
(2)外在因素:保养不当,缺乏对皮肤的护理,或不正确的皮肤护理程序。寒冷、干燥的气候,使得皮肤的各项机能减退,皮肤缺乏水分。过度暴露在阳光下,导致皮肤过度氧化,引起皮肤老化。造成皮肤衰老的主要原因是由于毛孔平常受到死亡细胞的阻塞。影响新陈代谢所致。
产生黑眼圈的原因如下:
(1)遗传体质及生理构造:当眼眶周围的皮肤特别薄,皮下组织又特别少时,当血流经过此处的大静脉,在特别接近皮肤表层下方便会出现蓝黑色的眼晕,看起来同黑眼圈。
(2)睡眠不足:眼周微血管较多,熬夜使眼睑得不到休息,血管持续紧张收缩,血流量长时间增加,引起眼圈皮下组织血管淤血和水肿,滞留下黯黑的阴影。
(3)久病体弱或大病初愈:由于眼周围皮下组织薄弱,皮肤易发生色素沉着,并极易显露在上、下眼睑上,出现一层黑圈。
(4)炎症:遗传性过敏症或过敏性接触皮炎,累及眼眶周围可出现黑眼圈。
(5)化妆品使用过度、吸烟、年老、月经不调、孕晚期、房事过度以及某些肝病和肾病都可能出现眼圈发黑。
然而,目前市面上的抗衰袪皱与淡化黑眼圈的产品存在很多问题,也没有一种产品可以一次性解决上述的皮肤问题,因此,急需要一种多功能效果良好的产品与制备方法,来确决本领域技术人员亟需解决的问题。而且现有技术的产品还存在抗衰袪皱与淡化黑眼圈的产品类别杂乱,效果不明显,周期长,而且致敏性高,刺激性大,易产生脂肪粒等问题。
发明内容
本发明实施例的目的在于提供一种祛眼袋的眼贴,旨在解决背景技术中提出的问题。
本发明实施例是这样实现的,一种祛眼袋的眼贴,其包括以下按照重量份计的组分:甘油2000~3000份、聚丙烯酸钠500~700份、甘羟铝14~22份、EDTA-2Na 6~10份、酒石酸20~28份、传明酸150~250份、烟酰胺75~125份、蛇毒肽100~200份、棕榈酰五肽-4 75~125份、透皮多肽35~65份、1,2-己二醇40~80份、对羟基苯乙酮40~80份、水4000~8000份。
作为本发明实施例的一个优选方案,所述眼贴包括以下按照重量份计的组分:甘油2300~2800份、聚丙烯酸钠550~650份、甘羟铝16~20份、EDTA-2Na 7~9份、酒石酸22~26份、传明酸170~230份、烟酰胺85~115份、蛇毒肽120~180份、棕榈酰五肽-4 85~115份、透皮多肽45~55份、1,2-己二醇50~70份、对羟基苯乙酮50~70份、水5000~7500份。
作为本发明实施例的另一个优选方案,所述眼贴包括以下按照重量份计的组分:甘油2500份、聚丙烯酸钠600份、甘羟铝18份、EDTA-2Na 8份、酒石酸25份、传明酸200份、烟酰胺100份、蛇毒肽150份、棕榈酰五肽-4 100份、透皮多肽50份、1,2-己二醇60份、对羟基苯乙酮60份、水6800份。
本发明实施例的另一目的在于提供一种上述眼贴的制备方法,其包括以下步骤:
按照上述各组分的重量份,称取甘油、聚丙烯酸钠、甘羟铝、EDTA-2Na、酒石酸、传明酸、烟酰胺、蛇毒肽、棕榈酰五肽-4、透皮多肽、1,2-己二醇、对羟基苯乙酮、水;
将甘油、聚丙烯酸钠、甘羟铝、EDTA-2Na进行混合,得到膏状半流体的A相;
将水、酒石酸、传明酸、烟酰胺、蛇毒肽、棕榈酰五肽-4、透皮多肽、1,2-己二醇、对羟基苯乙酮进行混合,得到B相;
将A相和B相置于真空环境下进行混合,得到胶体;
将胶体进行涂布处理,得到所述眼贴。
作为本发明实施例的另一个优选方案所述步骤中,真空环境的气压为0.05~0.08Pa。
本发明实施例的另一目的在于提供一种上述制备方法制得的眼贴。
本发明实施例的另一目的在于提供一种上述眼贴在制备祛眼袋、和/或抗皱、和/或祛斑、和/或祛黑眼圈的化妆品中的应用。
在本发明中:
甘油,是一种无色、无臭、有甜味、澄明的浓稠液体,在化学上名称为“丙三醇”。甘油通常是从油脂中提炼制成的。甘油具有很强的吸湿性,纯净的甘油能吸收40%的水分,所以搽在皮肤上能形成一层薄膜,有隔绝空气和防止水分蒸发的作用,还能吸收空气中的水分。所以,冬季人们常用甘油搽于手和面部等暴露在空气中的皮肤表面,能够使皮肤保持柔软,富有弹性,不受尘埃、气候等损害而干燥,起到防止皮肤冻伤的的作用。
聚丙稀酸钠,是一种新型功能高分子材料和重要化工产品,固态产品为白色(或浅黄色)块状或粉末,液态产品为无色(或淡黄色)粘稠液体。由丙烯酸及其酯类为原料,经水溶液聚合而得。无味,溶于氢氧化钠水溶液,在氢氧化钙、氢氧化镁等水溶液中发生沉淀。常被用作水处理剂、盐水精制及胶乳增稠,也可用作食品增粘、乳化。
甘羟铝,其化学名为二羟基氨基乙酸铝,与聚丙烯酸钠起胶联作用。
EDTA-2Na,即乙二胺四乙酸二钠,是化学中一种良好的配合剂,它有六个配位原子,为白色结晶颗粒或粉末,无臭、无味,能溶于水,极难溶于乙醇。它是可以防止金属引起的变色、变质、变浊和维生素C的氧化损失,还能提高油脂的抗氧化性(油脂中的微量金属如铁、铜等有促进油脂氧化的作用)。
酒石酸,即2,3-二羟基丁二酸,是一种羧酸,存在于多种植物中,如葡萄和罗望子,也是葡萄酒中主要的有机酸之一。在配方中起调节pH值作用。
传明酸,一般指氨甲环酸。氨甲环酸(Tranexamic acid)又名凝血酸,化学名为反-4-氨甲基环已烷甲酸,白色结晶性粉末;无臭,味微苦。在水中易溶,在医学界称之为断血炎,作为凝血剂用途,诊治过程意外发现有使肌肤变白的副作用。传明酸的美白机制是同时且迅速的抑制酪胺酸脢酵素和黑色素细胞的活性,并且防止黑色素聚集的情况,能阻断消弭因为紫外线照射而形成黑色素恶化的行进路径,从而有效的防止和改善皮肤的色素沉积。
烟酰胺,又称尼克酰胺,是烟酸的酰胺化合物。其为白色的结晶性粉末;无臭或几乎无臭,味苦;略有引湿性。在水或乙醇中易溶,在甘油中溶解。主要功能是保湿,美白,去皱,减少痤疮。
蛇毒肽,是一种模拟蛇毒毒素WaglerinI活性的小肽,临床试验表明蛇毒肽能够通过抑制肌肉收缩而减少皱纹的产生,具有优秀的光滑和迅速祛皱性能。蛇毒肽通过松弛面部肌肉而作为有效的平滑和祛皱活性产品,该活性三肽作用方式与TempleViper毒蛇毒液的神经肌肉阻断化合物Waglerin1一致。蛇毒肽作用于突触后膜,是肌肉烟碱乙酰胆碱受体(nmAChR)可逆转的拮抗剂。蛇毒肽结合nmAChR的ε亚单位从而阻滞乙酰胆碱与受体的结合,最终导致受体封闭,在封闭状态下钠离子不能摄入,无法去极化,神经兴奋传递阻断,肌肉因此松弛。
棕榈酰五肽-4,又名M基肽或者棕榈酰五肽-3。 英文名称是:PalmitoylPentapeptide-4/Matrixyl Acetate ,CAS号:214047-00-4。其作为一种信使肽,刺激皮肤真皮层中胶原蛋白(型、型、型)和弹性蛋白的合成和发展,具有抗皱抗衰老、改善皮肤质量的功效,常用于脸部、颈部和手护理品等美容护肤品中,如乳液、面膜、早晚霜、眼部精华液等。另外。棕榈酰五肽-4为胜肽系列应用最早和最广泛的多胜肽,国内外知名品牌普遍采用作为抗皱配方重要成分,在很多抗皱护肤产品中经常出现它的身影。它可以穿透真皮增加胶原蛋白,通过从内至外的重建来逆转皮肤老化的过程;刺激胶原蛋白、弹力纤维和透明质酸增生,提高肌肤的含水量和锁水度,增加皮肤厚度以及减少细纹。
透皮多肽,具有主动修复,激活再生细胞的功能,改善肤质,调理皮肤敏感,刺激,过敏,提亮肤色,提高皮肤弹性,令肌肤紧致光滑,淡化细纹的作用。
1,2-己二醇,又名“甘醇”、“1,2-亚乙基二醇”,简称EG。化学式为(CH2OH)2,是最简单的二元醇。乙二醇是无色无臭、有甜味液体,是一款对人体无害的保湿剂和防腐剂。
对羟基苯乙酮,(英文名称p-Hydroxyacetophenone)又名4-羟基苯乙酮(4-Hydroxyacetophenone),4-乙酰基苯酚(4-Acetylphenol),对乙酰基苯酚(p-Acetylphenol),4-羟苯基甲基酮(4-hydroxyphenyl methyl ketone),俗称针枞酚(piceol),常温下为白色针状结晶,可燃,易溶于热水,甲醇、乙醇、乙醚、丙酮、苯,难溶于石油醚。对羟基苯乙酮天然存在于菊科植物滨蒿的茎、叶,茵陈蒿、萝藦科植物人参娃儿藤等植物的根中,在配方中起防腐作用。
本发明实施例提供的一种祛眼袋的眼贴,与现在市面上销售的大部分化妆品相比,具有显著的协同作用,其抗氧化抗衰老效果明显,且具有美白祛斑的效果十分出众不容易产生药物依赖性等优点,适合广大消费者使用。通过使用本发明的眼贴适用更多的不同肤质人群,适用范围广,并且用户使用后,皱纹明显减轻,皮肤弹性明显增加,具有较好的抗衰老效果。
另外,本发明提供的眼贴对面部肤色暗沉、色素沉着等肌肤问题具有明显的改善作用;还具有清除自由基、抗氧化、提高角质细胞的细胞活力,修复皮肤组织的作用;可改善面部皮肤组织松弛萎缩导致的皱纹,对眼袋具有一定程度的驱除作用。
具体实施方式
为了使本发明的目的、技术方案及优点更加清楚明白,以下结合实施例,对本发明进行进一步详细说明。应当理解,此处所描述的具体实施例仅仅用以解释本发明,并不用于限定本发明。
实施例1
该实施例提供了一种祛眼袋的眼贴,其制备方法包括以下步骤:
S1、称取甘油2000g、聚丙烯酸钠500g、甘羟铝14g、EDTA-2Na 6g、酒石酸20g、传明酸150g、烟酰胺75g、蛇毒肽100g、棕榈酰五肽-4 75g、透皮多肽35g、1,2-己二醇40g、对羟基苯乙酮40g、纯净水8000g,备用。
S2、往搅拌器中加入上述称取的甘油,然后加入上述称取的聚丙烯酸钠、甘羟铝、EDTA-2Na进行搅拌混合10min,直至形成均匀膏状半流体,无肉眼可见的粉体颗粒,得到A相。
S3、往另一容器中加入上述称取的纯净水、酒石酸、传明酸、烟酰胺、蛇毒肽、棕榈酰五肽-4、透皮多肽、1,2-己二醇、对羟基苯乙酮进行搅拌混合至完全溶解,并持续搅拌10min后,静置,待溶液变得粘稠且无肉眼可见不溶物后,停止搅拌,得到B相。
S4、将上述得到的B相加入真空双行星动力搅拌器中,然后加入上述得到的A相,同时将真空双行星动力搅拌器开启真空直至气压为0.05Pa后,再快速搅拌5min至形成粘稠的胶体。
S5、将上述胶体置于涂布机中进行涂布处理后,再进行固化处理8h,并经分切包装,即可得到眼贴。
实施例2
该实施例提供了一种祛眼袋的眼贴,其制备方法包括以下步骤:
S1、称取甘油3000g、聚丙烯酸钠700g、甘羟铝22g、EDTA-2Na 10g、酒石酸28g、传明酸250g、烟酰胺125g、蛇毒肽200g、棕榈酰五肽-4 125g、透皮多肽65g、1,2-己二醇80g、对羟基苯乙酮80g、纯净水4000g,备用。
S2、往搅拌器中加入上述称取的甘油,然后加入上述称取的聚丙烯酸钠、甘羟铝、EDTA-2Na进行搅拌混合10min,直至形成均匀膏状半流体,无肉眼可见的粉体颗粒,得到A相。
S3、往另一容器中加入上述称取的纯净水、酒石酸、传明酸、烟酰胺、蛇毒肽、棕榈酰五肽-4、透皮多肽、1,2-己二醇、对羟基苯乙酮进行搅拌混合至完全溶解,并持续搅拌20min后,静置,待溶液变得粘稠且无肉眼可见不溶物后,停止搅拌,得到B相。
S4、将上述得到的B相加入真空双行星动力搅拌器中,然后加入上述得到的A相,同时将真空双行星动力搅拌器开启真空直至气压为0.08Pa后,再快速搅拌8min至形成粘稠的胶体。
S5、将上述胶体置于涂布机中进行涂布处理后,再进行固化处理12h,并经分切包装,即可得到眼贴。
实施例3
该实施例提供了一种祛眼袋的眼贴,其制备方法包括以下步骤:
S1、称取甘油2800g、聚丙烯酸钠650g、甘羟铝20g、EDTA-2Na 9g、酒石酸26g、传明酸230g、烟酰胺115g、蛇毒肽180g、棕榈酰五肽-4 115g、透皮多肽55g、1,2-己二醇70g、对羟基苯乙酮70g、水5000g,备用。
S2、往搅拌器中加入上述称取的甘油,然后加入上述称取的聚丙烯酸钠、甘羟铝、EDTA-2Na进行搅拌混合10min,直至形成均匀膏状半流体,无肉眼可见的粉体颗粒,得到A相。
S3、往另一容器中加入上述称取的纯净水、酒石酸、传明酸、烟酰胺、蛇毒肽、棕榈酰五肽-4、透皮多肽、1,2-己二醇、对羟基苯乙酮进行搅拌混合至完全溶解,并持续搅拌15min后,静置,待溶液变得粘稠且无肉眼可见不溶物后,停止搅拌,得到B相。
S4、将上述得到的B相加入真空双行星动力搅拌器中,然后加入上述得到的A相,同时将真空双行星动力搅拌器开启真空直至气压为0.06Pa后,再快速搅拌6min至形成粘稠的胶体。
S5、将上述胶体置于涂布机中进行涂布处理后,再进行固化处理10h,并经分切包装,即可得到眼贴。
实施例4
该实施例提供了一种祛眼袋的眼贴,其制备方法包括以下步骤:
S1、称取甘油2300g、聚丙烯酸钠550g、甘羟铝16g、EDTA-2Na 7g、酒石酸22g、传明酸170g、烟酰胺85g、蛇毒肽120g、棕榈酰五肽-4 85g、透皮多肽45g、1,2-己二醇50g、对羟基苯乙酮50g、水7500g,备用。
S2、往搅拌器中加入上述称取的甘油,然后加入上述称取的聚丙烯酸钠、甘羟铝、EDTA-2Na进行搅拌混合10min,直至形成均匀膏状半流体,无肉眼可见的粉体颗粒,得到A相。
S3、往另一容器中加入上述称取的纯净水、酒石酸、传明酸、烟酰胺、蛇毒肽、棕榈酰五肽-4、透皮多肽、1,2-己二醇、对羟基苯乙酮进行搅拌混合至完全溶解,并持续搅拌10min后,静置,待溶液变得粘稠且无肉眼可见不溶物后,停止搅拌,得到B相。
S4、将上述得到的B相加入真空双行星动力搅拌器中,然后加入上述得到的A相,同时将真空双行星动力搅拌器开启真空直至气压为0.07Pa后,再快速搅拌6min至形成粘稠的胶体。
S5、将上述胶体置于涂布机中进行涂布处理后,再进行固化处理9h,并经分切包装,即可得到眼贴。
实施例5
该实施例提供了一种祛眼袋的眼贴,其制备方法包括以下步骤:
S1、称取甘油2500g、聚丙烯酸钠600g、甘羟铝18g、EDTA-2Na 8g、酒石酸25g、传明酸200g、烟酰胺100g、蛇毒肽150g、棕榈酰五肽-4 100g、透皮多肽50g、1,2-己二醇60g、对羟基苯乙酮60g、水6800g,备用。
S2、往搅拌器中加入上述称取的甘油,然后加入上述称取的聚丙烯酸钠、甘羟铝、EDTA-2Na进行搅拌混合10min,直至形成均匀膏状半流体,无肉眼可见的粉体颗粒,得到A相。
S3、往另一容器中加入上述称取的纯净水、酒石酸、传明酸、烟酰胺、蛇毒肽、棕榈酰五肽-4、透皮多肽、1,2-己二醇、对羟基苯乙酮进行搅拌混合至完全溶解,并持续搅拌15min后,静置,待溶液变得粘稠且无肉眼可见不溶物后,停止搅拌,得到B相。
S4、将上述得到的B相加入真空双行星动力搅拌器中,然后加入上述得到的A相,同时将真空双行星动力搅拌器开启真空直至气压为0.06Pa后,再快速搅拌6min至形成粘稠的胶体。
S5、将上述胶体置于涂布机中进行涂布处理后,再进行固化处理10h,并经分切包装,即可得到眼贴。
实验例:
对上述实施例1~5制得的眼贴进行使用效果测试评估,具体如下:
1、试验品:实施例1~5制得的眼贴。
2、受试人群:年龄为25~50岁之间的100名女性。
3、试用周期:60天。
4、试用方法:每两天一次,将眼贴敷在眼部20~30min即可。
5、健康状况:受试者皮肤健康,无皮肤病过敏史,符合受试者志愿入选标准。
6、测试评估结果如表1~5所示,表中的数字代表对应评价项目的人数:
表1、实施例1制得的眼贴的试用反馈总结表
评价项目 | 很好 | 好 | 一般 | 较差 | 很差 | 其它 |
肌肤光滑与弹性 | 70 | 16 | 14 | 0 | 0 | 无过敏 |
保湿度 | 65 | 17 | 18 | 0 | 0 | 无过敏 |
祛皱纹 | 72 | 18 | 9 | 1 | 0 | 无过敏 |
祛黑眼圈 | 78 | 14 | 5 | 3 | 0 | 无过敏 |
祛眼袋 | 45 | 31 | 24 | 0 | 0 | 无过敏 |
表2、实施例2制得的眼贴的试用反馈总结表
评价项目 | 很好 | 好 | 一般 | 较差 | 很差 | 其它 |
肌肤光滑与弹性 | 63 | 17 | 18 | 2 | 0 | 无过敏 |
保湿度 | 61 | 22 | 17 | 0 | 0 | 无过敏 |
祛皱纹 | 68 | 17 | 14 | 1 | 0 | 无过敏 |
祛黑眼圈 | 70 | 17 | 10 | 3 | 0 | 无过敏 |
祛眼袋 | 38 | 37 | 25 | 0 | 0 | 无过敏 |
表3、实施例3制得的眼贴的试用反馈总结表
评价项目 | 很好 | 好 | 一般 | 较差 | 很差 | 其它 |
肌肤光滑与弹性 | 83 | 10 | 7 | 0 | 0 | 无过敏 |
保湿度 | 85 | 9 | 6 | 0 | 0 | 无过敏 |
祛皱纹 | 87 | 8 | 3 | 2 | 0 | 无过敏 |
祛黑眼圈 | 75 | 15 | 9 | 1 | 0 | 无过敏 |
祛眼袋 | 45 | 25 | 28 | 2 | 0 | 无过敏 |
表4、实施例4制得的眼贴的试用反馈总结表
评价项目 | 很好 | 好 | 一般 | 较差 | 很差 | 其它 |
肌肤光滑与弹性 | 85 | 10 | 5 | 0 | 0 | 无过敏 |
保湿度 | 90 | 7 | 3 | 0 | 0 | 无过敏 |
祛皱纹 | 92 | 6 | 2 | 0 | 0 | 无过敏 |
祛黑眼圈 | 80 | 8 | 12 | 0 | 0 | 无过敏 |
祛眼袋 | 83 | 6 | 10 | 1 | 0 | 无过敏 |
表5、实施例5制得的眼贴的试用反馈总结表
评价项目 | 很好 | 好 | 一般 | 较差 | 很差 | 其它 |
肌肤光滑与弹性 | 98 | 2 | 0 | 0 | 0 | 无过敏 |
保湿度 | 95 | 4 | 1 | 0 | 0 | 无过敏 |
祛皱纹 | 92 | 8 | 0 | 0 | 0 | 无过敏 |
祛黑眼圈 | 93 | 2 | 5 | 0 | 0 | 无过敏 |
祛眼袋 | 97 | 1 | 2 | 0 | 0 | 无过敏 |
测试者均表示,在肤感、增加眼周肌肤光滑、弹性及祛皱、祛黑眼圈、袪眼袋等功效方面,实施例1~5制得的眼贴均起到很好的效果,其中,实施例5制备产品优于实施例1~4所制得的眼贴,测试者均对实施例5制得的眼贴尤为认可。
以上所述实施例仅表达了本发明的几种实施方式,其描述较为具体和详细,但并不能因此而理解为对本发明专利范围的限制。应当指出的是,对于本领域的普通技术人员来说,在不脱离本发明构思的前提下,还可以做出若干变形和改进,这些都属于本发明的保护范围。因此,本发明专利的保护范围应以所附权利要求为准。
Claims (7)
1.一种祛眼袋的眼贴,其特征在于,包括以下按照重量份计的组分:甘油2000~3000份、聚丙烯酸钠500~700份、甘羟铝14~22份、EDTA-2Na 6~10份、酒石酸20~28份、传明酸150~250份、烟酰胺75~125份、蛇毒肽100~200份、棕榈酰五肽-4 75~125份、透皮多肽35~65份、1,2-己二醇40~80份、对羟基苯乙酮40~80份、水4000~8000份。
2.根据权利要求1所述的一种祛眼袋的眼贴,其特征在于,所述眼贴包括以下按照重量份计的组分:甘油2300~2800份、聚丙烯酸钠550~650份、甘羟铝16~20份、EDTA-2Na 7~9份、酒石酸22~26份、传明酸170~230份、烟酰胺85~115份、蛇毒肽120~180份、棕榈酰五肽-4 85~115份、透皮多肽45~55份、1,2-己二醇50~70份、对羟基苯乙酮50~70份、水5000~7500份。
3.根据权利要求1或2所述的一种祛眼袋的眼贴,其特征在于,所述眼贴包括以下按照重量份计的组分:甘油2500份、聚丙烯酸钠600份、甘羟铝18份、EDTA-2Na 8份、酒石酸25份、传明酸200份、烟酰胺100份、蛇毒肽150份、棕榈酰五肽-4 100份、透皮多肽50份、1,2-己二醇60份、对羟基苯乙酮60份、水6800份。
4.一种如权利要求1~3中任一项所述眼贴的制备方法,其特征在于,包括以下步骤:
按照上述各组分的重量份,称取甘油、聚丙烯酸钠、甘羟铝、EDTA-2Na、酒石酸、传明酸、烟酰胺、蛇毒肽、棕榈酰五肽-4、透皮多肽、1,2-己二醇、对羟基苯乙酮、水;
将甘油、聚丙烯酸钠、甘羟铝、EDTA-2Na进行混合,得到膏状半流体的A相;
将水、酒石酸、传明酸、烟酰胺、蛇毒肽、棕榈酰五肽-4、透皮多肽、1,2-己二醇、对羟基苯乙酮进行混合,得到B相;
将A相和B相置于真空环境下进行混合,得到胶体;
将胶体进行涂布处理,得到所述眼贴。
5.根据权利要求4所述的一种祛眼袋的眼贴的制备方法,其特征在于,所述步骤中,真空环境的气压为0.05~0.08Pa。
6.一种如权利要求4~5中任一项所述制备方法制得的眼贴。
7.一种如权利要求1~3和权利要求6中任一项所述眼贴在制备祛眼袋、和/或抗皱、和/或祛斑、和/或祛黑眼圈的化妆品中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110013939.1A CN112618414A (zh) | 2021-01-06 | 2021-01-06 | 一种祛眼袋的眼贴及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110013939.1A CN112618414A (zh) | 2021-01-06 | 2021-01-06 | 一种祛眼袋的眼贴及其制备方法和应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN112618414A true CN112618414A (zh) | 2021-04-09 |
Family
ID=75291591
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110013939.1A Pending CN112618414A (zh) | 2021-01-06 | 2021-01-06 | 一种祛眼袋的眼贴及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112618414A (zh) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108685764A (zh) * | 2018-08-31 | 2018-10-23 | 友杰医药科技(上海)有限公司 | 一种改善眼周问题的组合物、制备方法及其应用 |
CN108852894A (zh) * | 2018-06-13 | 2018-11-23 | 浙江湃肽生物有限公司 | 一种用于修复美白祛皱的多肽组合 |
CN110604711A (zh) * | 2019-10-17 | 2019-12-24 | 广州市玉鑫化妆品有限公司 | 一种多效眼贴膜及其制备方法 |
CN111467274A (zh) * | 2020-04-30 | 2020-07-31 | 深圳市垂纶远翔科技有限责任公司 | 一种快速祛皱祛眼袋的眼霜 |
CN111973506A (zh) * | 2020-07-23 | 2020-11-24 | 广州市科能化妆品科研有限公司 | 一种抗皱、祛黑眼圈、祛眼袋的组合物及其应用 |
-
2021
- 2021-01-06 CN CN202110013939.1A patent/CN112618414A/zh active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108852894A (zh) * | 2018-06-13 | 2018-11-23 | 浙江湃肽生物有限公司 | 一种用于修复美白祛皱的多肽组合 |
CN108685764A (zh) * | 2018-08-31 | 2018-10-23 | 友杰医药科技(上海)有限公司 | 一种改善眼周问题的组合物、制备方法及其应用 |
CN110604711A (zh) * | 2019-10-17 | 2019-12-24 | 广州市玉鑫化妆品有限公司 | 一种多效眼贴膜及其制备方法 |
CN111467274A (zh) * | 2020-04-30 | 2020-07-31 | 深圳市垂纶远翔科技有限责任公司 | 一种快速祛皱祛眼袋的眼霜 |
CN111973506A (zh) * | 2020-07-23 | 2020-11-24 | 广州市科能化妆品科研有限公司 | 一种抗皱、祛黑眼圈、祛眼袋的组合物及其应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104188885B (zh) | 一种滋润保湿型紫草润唇膏及其制备方法 | |
CN105125476A (zh) | 一种抗皱精华液及其制备方法 | |
CN109106664A (zh) | 具有保湿舒缓修护功效的组合物、面膜及其制备方法 | |
CN107496325A (zh) | 含牡丹精油、青瓜提取液和蜗牛原液的面膜及其制备方法 | |
CN110772463B (zh) | 眼部肌肤修复组合物及其制备方法和应用 | |
CN106580762A (zh) | 具有抚纹抗皱功效的护肤品组合物、眼霜及其制备方法 | |
CN104983646A (zh) | 夜用养护面膜液及其制备方法 | |
CN105267118A (zh) | 一种含天然成分提取物的美白保湿精华液及其制备方法与应用 | |
CN104546650A (zh) | 一种紧致肌肤的面膜及其制作方法 | |
CN109260116A (zh) | 一种含有植物提取物的至肽肌底液及其生产工艺 | |
CN105496886B (zh) | 植物鞘氨醇护肤液 | |
CN104490713A (zh) | 一种具有排浊紧致和抗皱活化肌肤功能的超软活泉护肤品 | |
CN102266280A (zh) | 精制鹿油在制备保湿化妆品中的应用 | |
CN113768853B (zh) | 一种美白淡斑组合物及其制备方法和应用 | |
CN104825347A (zh) | 一种医用生物美白袪斑敷料及其制备方法 | |
CN105267123A (zh) | 一种美白保湿爽肤水及其制备方法 | |
CN106333880B (zh) | 一种稀薄乳液基质的爽肤水及其制备方法 | |
CN106361667B (zh) | 蛇油膏 | |
CN107519118A (zh) | 一种蛇胆眼膜及其制备方法 | |
CN102266275B (zh) | 精制鹿油在制备抗皱化妆品中应用 | |
CN104224676A (zh) | 螺旋藻抗皱防衰老面膜 | |
CN103565693B (zh) | 一种滋润护肤乳液及其制备方法 | |
CN109771326A (zh) | 一种用于美白修护面膜的组合物 | |
CN112618414A (zh) | 一种祛眼袋的眼贴及其制备方法和应用 | |
EP3470116A1 (en) | Cosmetic composition for skin and use of a cosmetic composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210409 |
|
RJ01 | Rejection of invention patent application after publication |